FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310106476> ?p ?o ?g. }

• W4310106476 endingPage "7449" @default.
• W4310106476 startingPage "7447" @default.
• W4310106476 abstract "Introduction CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy has shown high overall response rates (ORRs) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL); however, CD19 CAR-T cells fail to elicit a complete response (CR) in a considerable proportion of pts. PD-L1 expression in the tumor microenvironment could impair the efficacy of CAR-T cell therapy. PD-1/PD-L1 pathway blockade may enhance the function and antitumor activity of CAR-T cells. Here, we report the analysis of a phase I dose-finding study (NCT02706405) of combination therapy with CD19-targeted 4-1BB-costimulated CAR-T cells (JCAR014) and escalating doses of durvalumab (durva), an anti-PD-L1 monoclonal antibody, in adults with R/R LBCL. Methods Pts were treated in 1 of 2 groups. All pts received lymphodepletion (LD) with cyclophosphamide (Cy) and fludarabine (Flu) followed by JCAR014 infusion. Pts in group 1 (Grp 1) received the first dose of durva (225 mg or 750 mg) after JCAR014 infusion. Pts in group 2 (Grp 2) received the first dose of durva (7.5 mg, 22.5 mg, 75 mg, 225 mg, or 750 mg) 1 day prior to JCAR014 infusion. Up to 10 doses of durva were administered at 4-week intervals after JCAR014 at the highest identified safe dose until toxicity or disease progression. Adverse events (AEs) were graded by CTCAE 4.03, except for cytokine release syndrome (CRS), which was graded according to Lee 2014 consensus criteria. Response was reported according to PET/CT 2014 Lugano criteria. Results Between 01/23/2017 and 07/02/2020, 34 pts were screened, 32 underwent leukapheresis, and 29 were enrolled and received LD and JCAR014. Eleven pts were treated in Grp 1 and 18 in Grp 2 (Table 1). All pts received 2 x 106 JCAR014 cells/kg, except for the first 2 pts treated on the study who received 7 x 105 cells/kg. The most common AEs of any grade related to LD and JCAR014 with or without durva were CRS (41%), neutropenia (21%), neurotoxicity (17%), and hypogammaglobulinemia (17%). The incidences of any grade and grade ≥ 3 CRS and neurotoxicity were similar between Grp 1 and Grp 2 (Table 2A). Patients in Grp 2 had later onset of CRS after JCAR014 infusion compared with Grp 1 (median of 6 vs. 4 days, P = .05) and shorter duration of CRS (median of 3 vs. 8 days, P = .08). Among the 27 pts evaluable for dose-limiting toxicity (DLT), 2 (7%) had DLT: 1 pt with grade 4 CRS in Grp 2 (durva 225 mg) and 1 pt with prolonged grade 3 neurotoxicity in Grp 2 (durva 750 mg). No maximum-tolerated dose of durva was identified. In pts evaluable for response (n = 26), the ORR and the CR rate at 3 months were 35% (95% CI, 17-56) and 27% (95% CI, 14-46). We retrospectively compared the response rates of LBCL pts treated with JCAR014 in combination with durva (NCT02706405) with LBCL pts who received the same Cy/Flu lymphodepletion regimen and JCAR014 dose (2 x 106 cells/kg) without durva (JCAR014 alone cohort) on our previous phase I/II clinical trial (NCT01865617). There was a trend towards lower ORR (P = .08) and CR rate (P = .09) in pts treated with JCAR014 in combination with durva compared with those treated in the JCAR014 alone cohort (Table 2B). There were no significant differences in ORR and CR rate between patients in Grp 1 and those who received JCAR014 alone. However, despite a trend towards lower tumor burden, pts in Grp 2 (first durva before JCAR014) had lower ORR (P = .07) and CR rate (P = .03) compared with those treated in the JCAR014 alone cohort, and a trend towards lower CR rate compared with those treated in Grp 1 (first durva after JCAR014; P = .16). Patients treated with JCAR014 alone had significantly shorter time to CAR-T cell peak counts in blood compared with patients treated with JCAR014 in combination with durva (median of 8 vs. 14 days, P = .01). We did not observe significant differences in peak CAR-T cell expansion, area under the curve (AUC) from day 0 to 28 after JCAR014 infusion, and day 28 CAR-T cell counts by qPCR between the cohorts. Conclusion The combination of JCAR014 with durva for the treatment of adult pts with LBCL was safe. Our findings suggest that the timing of initiation of durva therapy is a key variable that may affect outcomes. To our knowledge, this is the first report suggesting that PD-L1 blockade may impact toxicity and antitumor response in pts with LBCL undergoing CD19 CAR-T cell therapy. Additional studies will be required to determine the optimal approach for combining CD19 CAR-T cell therapy with PD-1/PD-L1 pathway blockade in LBCL. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310106476 created "2022-11-30" @default.
• W4310106476 creator A5007024434 @default.
• W4310106476 creator A5007310385 @default.
• W4310106476 creator A5010158325 @default.
• W4310106476 creator A5015232526 @default.
• W4310106476 creator A5015772761 @default.
• W4310106476 creator A5016684714 @default.
• W4310106476 creator A5019486752 @default.
• W4310106476 creator A5026596540 @default.
• W4310106476 creator A5035086451 @default.
• W4310106476 creator A5037938194 @default.
• W4310106476 creator A5043131622 @default.
• W4310106476 creator A5053485062 @default.
• W4310106476 creator A5055685996 @default.
• W4310106476 creator A5057524392 @default.
• W4310106476 creator A5060993908 @default.
• W4310106476 creator A5071844603 @default.
• W4310106476 creator A5082784821 @default.
• W4310106476 creator A5087281332 @default.
• W4310106476 creator A5089990813 @default.
• W4310106476 date "2022-11-15" @default.
• W4310106476 modified "2023-10-10" @default.
• W4310106476 title "Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma" @default.
• W4310106476 doi "https://doi.org/10.1182/blood-2022-168185" @default.
• W4310106476 hasPublicationYear "2022" @default.
• W4310106476 type Work @default.
• W4310106476 citedByCount "1" @default.
• W4310106476 countsByYear W43101064762023 @default.
• W4310106476 crossrefType "journal-article" @default.
• W4310106476 hasAuthorship W4310106476A5007024434 @default.
• W4310106476 hasAuthorship W4310106476A5007310385 @default.
• W4310106476 hasAuthorship W4310106476A5010158325 @default.
• W4310106476 hasAuthorship W4310106476A5015232526 @default.
• W4310106476 hasAuthorship W4310106476A5015772761 @default.
• W4310106476 hasAuthorship W4310106476A5016684714 @default.
• W4310106476 hasAuthorship W4310106476A5019486752 @default.
• W4310106476 hasAuthorship W4310106476A5026596540 @default.
• W4310106476 hasAuthorship W4310106476A5035086451 @default.
• W4310106476 hasAuthorship W4310106476A5037938194 @default.
• W4310106476 hasAuthorship W4310106476A5043131622 @default.
• W4310106476 hasAuthorship W4310106476A5053485062 @default.
• W4310106476 hasAuthorship W4310106476A5055685996 @default.
• W4310106476 hasAuthorship W4310106476A5057524392 @default.
• W4310106476 hasAuthorship W4310106476A5060993908 @default.
• W4310106476 hasAuthorship W4310106476A5071844603 @default.
• W4310106476 hasAuthorship W4310106476A5082784821 @default.
• W4310106476 hasAuthorship W4310106476A5087281332 @default.
• W4310106476 hasAuthorship W4310106476A5089990813 @default.
• W4310106476 hasConcept C126322002 @default.
• W4310106476 hasConcept C143998085 @default.
• W4310106476 hasConcept C197934379 @default.
• W4310106476 hasConcept C203014093 @default.
• W4310106476 hasConcept C2776090121 @default.
• W4310106476 hasConcept C2776694085 @default.
• W4310106476 hasConcept C2776755627 @default.
• W4310106476 hasConcept C2779263901 @default.
• W4310106476 hasConcept C2780850621 @default.
• W4310106476 hasConcept C3875195 @default.
• W4310106476 hasConcept C71924100 @default.
• W4310106476 hasConcept C8891405 @default.
• W4310106476 hasConcept C90924648 @default.
• W4310106476 hasConceptScore W4310106476C126322002 @default.
• W4310106476 hasConceptScore W4310106476C143998085 @default.
• W4310106476 hasConceptScore W4310106476C197934379 @default.
• W4310106476 hasConceptScore W4310106476C203014093 @default.
• W4310106476 hasConceptScore W4310106476C2776090121 @default.
• W4310106476 hasConceptScore W4310106476C2776694085 @default.
• W4310106476 hasConceptScore W4310106476C2776755627 @default.
• W4310106476 hasConceptScore W4310106476C2779263901 @default.
• W4310106476 hasConceptScore W4310106476C2780850621 @default.
• W4310106476 hasConceptScore W4310106476C3875195 @default.
• W4310106476 hasConceptScore W4310106476C71924100 @default.
• W4310106476 hasConceptScore W4310106476C8891405 @default.
• W4310106476 hasConceptScore W4310106476C90924648 @default.
• W4310106476 hasIssue "Supplement 1" @default.
• W4310106476 hasLocation W43101064761 @default.
• W4310106476 hasOpenAccess W4310106476 @default.
• W4310106476 hasPrimaryLocation W43101064761 @default.
• W4310106476 hasRelatedWork W2349603434 @default.
• W4310106476 hasRelatedWork W2916176185 @default.
• W4310106476 hasRelatedWork W2917403768 @default.
• W4310106476 hasRelatedWork W2936186479 @default.
• W4310106476 hasRelatedWork W2952260713 @default.
• W4310106476 hasRelatedWork W2969241243 @default.
• W4310106476 hasRelatedWork W3142239825 @default.
• W4310106476 hasRelatedWork W4220818326 @default.
• W4310106476 hasRelatedWork W4381594543 @default.
• W4310106476 hasRelatedWork W4385685231 @default.
• W4310106476 hasVolume "140" @default.
• W4310106476 isParatext "false" @default.
• W4310106476 isRetracted "false" @default.
• W4310106476 workType "article" @default.